Harpoon Therapeutics Provides An Update On The HPN217 Development And Option Agreement With AbbVie; AbbVie Has Notified The Company That It Will Not Exercise The Exclusive License Option Of The Parties' Development And Option Agreement
Portfolio Pulse from Benzinga Newsdesk
Harpoon Therapeutics announced that AbbVie will not exercise the exclusive license option of the HPN217 program, as per their Development and Option Agreement. The agreement will terminate on October 12, 2023. Harpoon will retain exclusive ownership of the HPN217 program and plans to complete the ongoing Phase 1 clinical trial.
September 13, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AbbVie has decided not to exercise the exclusive license option for Harpoon Therapeutics' HPN217 program.
The news impacts AbbVie as it indicates a decision not to pursue an exclusive license for Harpoon's HPN217 program. This could potentially affect AbbVie's product pipeline, but the overall impact may be limited given AbbVie's diverse portfolio.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 75
NEUTRAL IMPACT
Harpoon Therapeutics will retain exclusive ownership of the HPN217 program and continue the Phase 1 clinical trial, following AbbVie's decision not to exercise the exclusive license option.
The news directly impacts Harpoon Therapeutics as it pertains to their HPN217 program. The company's decision to continue the Phase 1 clinical trial could potentially lead to positive outcomes, but the lack of partnership with AbbVie may also present challenges.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100